IL91322A - Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract - Google Patents

Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract

Info

Publication number
IL91322A
IL91322A IL9132289A IL9132289A IL91322A IL 91322 A IL91322 A IL 91322A IL 9132289 A IL9132289 A IL 9132289A IL 9132289 A IL9132289 A IL 9132289A IL 91322 A IL91322 A IL 91322A
Authority
IL
Israel
Prior art keywords
fgf
acid
use according
sulfate
gastrointestinal tract
Prior art date
Application number
IL9132289A
Other languages
English (en)
Other versions
IL91322A0 (en
Original Assignee
Takeda Chemical Industries Ltd
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Childrens Medical Center filed Critical Takeda Chemical Industries Ltd
Publication of IL91322A0 publication Critical patent/IL91322A0/xx
Publication of IL91322A publication Critical patent/IL91322A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL9132289A 1988-08-19 1989-08-15 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract IL91322A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23496688A 1988-08-19 1988-08-19
US07/382,263 US5175147A (en) 1988-08-19 1989-07-20 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract

Publications (2)

Publication Number Publication Date
IL91322A0 IL91322A0 (en) 1990-03-19
IL91322A true IL91322A (en) 1994-12-29

Family

ID=26928432

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9132289A IL91322A (en) 1988-08-19 1989-08-15 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract

Country Status (16)

Country Link
US (2) US5175147A (de)
EP (1) EP0360006B1 (de)
JP (1) JP2501480B2 (de)
KR (1) KR920700040A (de)
CN (1) CN1040741A (de)
AT (1) ATE91628T1 (de)
CA (1) CA1330757C (de)
DE (1) DE68907679T2 (de)
DK (1) DK93890D0 (de)
ES (1) ES2058423T3 (de)
FI (2) FI901949A0 (de)
HU (1) HU207227B (de)
IE (1) IE63046B1 (de)
IL (1) IL91322A (de)
NO (1) NO901710D0 (de)
WO (1) WO1990001941A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
JPH0343088A (ja) * 1989-09-29 1991-02-25 Takeda Chem Ind Ltd ａＦＧＦ蛋白質の製造法
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
CA2020720A1 (en) * 1989-07-13 1991-01-14 Shigeko Yamazaki Method for the purification of therapeutically active recombinant acidic fibroblast growth factor
AUPN271295A0 (en) 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5739107A (en) 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
WO1992018153A1 (en) * 1991-04-12 1992-10-29 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
NO921495L (no) * 1991-04-16 1992-10-19 Seikagaku Kogyo Co Ltd Oligosakkarid og fremgangsmaate for dets fremstilling
US6190864B1 (en) 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
US5916772A (en) * 1992-06-16 1999-06-29 Whittier Institute For Diabetes And Endocrinology Recombinant production of saporin-containing proteins
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
FR2718023B1 (fr) * 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5531880A (en) * 1994-09-13 1996-07-02 Microelectronics And Computer Technology Corporation Method for producing thin, uniform powder phosphor for display screens
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
JP2004528005A (ja) * 2000-08-15 2004-09-16 ファージ バイオテクノロジー コーポレイション 生物学的に活性なタンパク質およびペプチドのファージ依存性超産生
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
EP3752174A4 (de) * 2018-02-13 2021-11-17 University of Florida Research Foundation, Incorporated Fibroblastenwachstumsfaktor-analoga und ihre verwendungen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
EP0105014B1 (de) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Wiederherstellung von Gewebe bei Tieren
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
JPS6028999A (ja) * 1983-06-30 1985-02-14 Maruho Kk 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
CA1207239A (en) * 1984-08-10 1986-07-08 Upendra K. Banik Gastrointestinal compositions
JPS6172947A (ja) * 1984-09-18 1986-04-15 Takasago Thermal Eng Co Ltd クリ−ンル−ムの形成法およびこの方法に使用する空気調和設備ユニツト
EP0248819B2 (de) * 1985-09-12 2000-08-30 Scios Inc. Rekombinanter fibroblast-wachstumsfaktor
WO1989000198A1 (en) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Recombinant fibroblast growth factors
DK122687A (da) * 1986-03-14 1987-09-15 Takeda Chemical Industries Ltd Polypeptid, dna og anvendelse deraf
CA1294546C (en) * 1986-04-23 1992-01-21 John S. Sundsmo Wound healing composition containing collagen
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
JPH01501840A (ja) * 1987-01-16 1989-06-29 アムジエン・インコーポレーテツド 繊維芽細胞成長因子の産生
JPH02504468A (ja) * 1987-11-24 1990-12-20 アムジエン・インコーポレーテツド 繊維芽細胞成長因子のアナログ
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
JPH0240399A (ja) * 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物

Also Published As

Publication number Publication date
AU630111B2 (en) 1992-10-22
IE892664L (en) 1990-02-19
FI943028L (fi) 1994-06-22
ATE91628T1 (de) 1993-08-15
HU207227B (en) 1993-03-29
FI943028A7 (fi) 1994-06-22
FI901949A7 (fi) 1990-04-18
US5175147A (en) 1992-12-29
CN1040741A (zh) 1990-03-28
KR920700040A (ko) 1992-02-19
EP0360006A2 (de) 1990-03-28
NO901710L (no) 1990-04-18
CA1330757C (en) 1994-07-19
NO901710D0 (no) 1990-04-18
DK93890A (da) 1990-04-17
EP0360006B1 (de) 1993-07-21
IE63046B1 (en) 1995-03-22
HUT55638A (en) 1991-06-28
IL91322A0 (en) 1990-03-19
DK93890D0 (da) 1990-04-17
DE68907679D1 (de) 1993-08-26
ES2058423T3 (es) 1994-11-01
DE68907679T2 (de) 1994-01-27
FI901949A0 (fi) 1990-04-18
HU895785D0 (en) 1990-12-28
AU4218989A (en) 1990-03-23
US5401721A (en) 1995-03-28
JPH03505736A (ja) 1991-12-12
EP0360006A3 (en) 1990-04-04
FI943028A0 (fi) 1994-06-22
WO1990001941A1 (en) 1990-03-08
JP2501480B2 (ja) 1996-05-29

Similar Documents

Publication Publication Date Title
US5401721A (en) Acid-resistant FGF composition for treating ulcerating diseases of the gastrointestinal tract
US5202311A (en) Stabilized fgf composition
US5234908A (en) Method of treating gastrointestinal ulcers with platelet derived growth factor
EP0706398B1 (de) Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält
US5314872A (en) Glucan sulfate, stabilized fibroblast growth factor composition
IE880499L (en) Novel insulin derivatives
CN113264994A (zh) 针对胰岛素抵抗的改良肽药物
US4598065A (en) Use of peptides as medicaments and certain novel peptides
EP0550035A2 (de) Stabilisierten Fibroblasten-Wachstumsfaktor enthaltende Zusammensetzung
US6673370B2 (en) Oxidized collagen formulations for use with non-compatible pharmaceutical agents
CA2220854A1 (en) Anti-ulcer composition
KR20010082272A (ko) 골대사이상증 치료제
AU630111C (en) Acid-resistant FGF composition and method of treating ulcerating diseases of the gastrointestinal tract
CA2108120C (en) Method of treating gastrointestinal ulcers with platelet derived growth factor
Fukunaga et al. Aluminium β‐cyclodextrin sulphate as a stabilizer and sustained‐release carrier for basic fibroblast growth factor
TW202241927A (zh) 一類用於修復皮膚損傷或黏膜損傷之多肽及其應用
WO1995007710A1 (en) Remedy for wound
Stapleton et al. Sucralfate in the prevention of porcine experimental peptic ulceration
RU2020931C1 (ru) Способ получения лекарственного средства для лечения язвенной болезни желудочно-кишечного тракта млекопитающих
US4720485A (en) Tripeptides for control of intestinal motility
WO1992008473A1 (en) Therapeutic use of fibroblast growth factor
WO1994028020A1 (en) A method for the preparation of interferons
JP3488721B2 (ja) 線維芽細胞成長因子安定化組成物
JPH10251162A (ja) 上部消化管疾患の予防および／または治療剤
CA2362664A1 (en) Utilization of orosomucoid in order to produce a pharmaceutical preparation